Literature DB >> 15858809

Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson's disease.

Reinoud C Klein1, Bauke M de Jong, Joeke J de Vries, Klaus L Leenders.   

Abstract

The differentiation between progressive supranuclear palsy (PSP) and Parkinson's disease (PD) may be difficult, especially in the early stages of disease. Positron emission tomography potentially provides a tool for making such a distinction. To identify key features in the spatial distributions of cerebral glucose metabolism, 18F-fluorodeoxyglucose (FDG) measurements of 10 patients with probable or possible PSP were directly compared with those of 9 PD patients. This analysis was done with statistic parametric mapping. After normalization of global brain uptake, in PSP, relative uptake of FDG was reduced in the caudal (motor) part of the anterior cingulate gyrus (Brodmann's area BA 24; P < 0.05, corrected for multiple comparisons). At a lower threshold, an additional decrease was present in the dorsal mesencephalon. In PD, relative hypometabolism was seen in extrastriate visual, ventrolateral temporal, posterior parietal, and orbitofrontal regions. Only reduction in the right fusiform gyrus and the lateral extrastriate visual cortex reached statistical significance. We concluded that particularly the reduction of medial frontal metabolism may be a valuable diagnostic imaging parameter in distinguishing PSP from PD. For PD, a possible association between occipitotemporal FDG decrease and vulnerability to hallucinations is suggested. Copyright 2005 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858809     DOI: 10.1002/mds.20493

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

Review 1.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

Review 2.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

3.  Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: Multivariate and univariate analyses in American and Chinese patient cohorts.

Authors:  Jingjie Ge; Jianjun Wu; Shichun Peng; Ping Wu; Jian Wang; Huiwei Zhang; Yihui Guan; David Eidelberg; Chuantao Zuo; Yilong Ma
Journal:  Hum Brain Mapp       Date:  2018-03-13       Impact factor: 5.038

4.  Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease.

Authors:  Andrea Varrone; Marco Pagani; Elena Salvatore; Dario Salmaso; Valeria Sansone; Marianna Amboni; Flavio Nobili; Giuseppe De Michele; Alessandro Filla; Paolo Barone; Sabina Pappatà; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-24       Impact factor: 9.236

Review 5.  Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism.

Authors:  Chae-Moon Hong; Ho-Sung Ryu; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

Review 6.  Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease.

Authors:  Yilong Ma; David Eidelberg
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

7.  Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury.

Authors:  Emilie Cornille; Mhamad Abou-Hamdan; Michel Khrestchatisky; André Nieoullon; Max de Reggi; Bouchra Gharib
Journal:  BMC Neurosci       Date:  2010-04-23       Impact factor: 3.288

8.  FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants.

Authors:  Nicholas Zalewski; Hugo Botha; Jennifer L Whitwell; Val Lowe; Dennis W Dickson; Keith A Josephs
Journal:  J Neurol       Date:  2014-02-04       Impact factor: 4.849

Review 9.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Authors:  Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

Review 10.  The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Authors:  Elizabeth A Mazzio; Fran Close; Karam F A Soliman
Journal:  Int J Mol Sci       Date:  2011-01-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.